AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38768299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP
Number of subjects: 69
Study 38768299 — intervention group
Group type: COMPARATOR
Intervention: BiVP
Number of subjects: 69
Study 38768299 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP and BiVP
Number of subjects: 69
Study 38768428 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI0101 (BCMA CART) therapy, 800 × 10^6 CART cells
Number of subjects: 50
Study 38768428 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI0101 (BCMA CART) therapy
Number of subjects: 50
Study 38768450 — intervention group
Group type: EXPERIMENTAL
Intervention: CADx-assisted histologic predictions
Number of subjects: 1252
Study 38768450 — intervention group
Group type: COMPARATOR
Intervention: CADx-unassisted histologic predictions
Number of subjects: 1252
Study 38768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive system invasion
Number of subjects: 172
Study 38768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Genitourinary system invasion
Number of subjects: 172
Study 38768462 — intervention group
Group type: COMPARATOR
Intervention: Gynecological system invasion
Number of subjects: 172
Study 38768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 172
Study 38768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of organs invaded by CRC
Number of subjects: 172
Study 38768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification based on age and type of organ invasion
Number of subjects: 172
Study 38768468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 330
Study 38768468 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 330
Study 38768617 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of BPaMZ (bedaquiline, pretomanid, moxifloxacin, pyrazinamide)
Number of subjects: 455
Study 38768617 — intervention group
Group type: COMPARATOR
Intervention: 6 months of HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 455
Study 38768617 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of BPaMZ
Number of subjects: 455
Study 38768617 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of BPaMZ
Number of subjects: 455
Study 38768617 — intervention group
Group type: COMPARATOR
Intervention: HRZE
Number of subjects: 455
Study 38768626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase (0.25 mg/kg)
Number of subjects: 886
Study 38768626 — intervention group
Group type: COMPARATOR
Intervention: Non-thrombolytic standard of care (control)
Number of subjects: 886
Study 38768839 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RF CA)
Number of subjects: 2470
Study 38768988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life inventory (PedsQL)
Number of subjects: 512
Study 38768988 — intervention group
Group type: EXPERIMENTAL
Intervention: 16D score
Number of subjects: 512
Study 38768988 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of care and transition readiness (quartile categorization)
Number of subjects: 512
Study 38769049 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and training on breastfeeding during antenatal visits, support by a trained female doctor, trained nurse at birth, and trained lady health worker at home for 6 months, supported by reading materials and videos via WhatsApp
Number of subjects: 50
Study 38769049 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and training on breastfeeding
Number of subjects: 50
Study 38769049 — intervention group
Group type: COMPARATOR
Intervention: Standard support provided within the hospital and at home
Number of subjects: 50
Study 38769221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related media exposure
Number of subjects: 8337
Study 38769221 — intervention group
Group type: EXPERIMENTAL
Intervention: Media consumption
Number of subjects: 8337
Study 38769284 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 6-month (PP6M) injection
Number of subjects: 700
Study 38769284 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 3-month (PP3M) injection
Number of subjects: 700
Study 38769314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpure chlorine dioxide
Number of subjects: 60
Study 38769314 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 60
Study 38769330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Number of subjects: 140
Study 38769330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (200 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Number of subjects: 140
Study 38769330 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 140
Study 38769330 — intervention group
Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 140
Study 38769431 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC (non-invasive spinal cord electrical stimulation)
Number of subjects: 0
Study 38769543 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIL therapy regimen (low-dose cyclophosphamide lymphodepletion followed by TIL infusion without intravenous IL-2)
Number of subjects: 14
Study 38769543 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIL therapy regimen
Number of subjects: 14
Study 38769552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower progesterone profile
Number of subjects: 95
Study 38769552 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper progesterone profile
Number of subjects: 95
Study 38769552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum 17-hydroxyprogesterone profile
Number of subjects: 95
Study 38769552 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper serum 17-hydroxyprogesterone profile
Number of subjects: 95
Study 38769562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes group (HbA1c 5.7-6.4%)
Number of subjects: 3910
Study 38769562 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia group (HbA1c < 5.7%)
Number of subjects: 3910
Study 38769562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group (HbA1c ≥ 6.5%)
Number of subjects: 3910
Study 38769624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene measures and mindfulness meditation (relaxation audio) for 5 weeks
Number of subjects: 36
Study 38769624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guidance for therapies)
Number of subjects: 36
Study 38769643 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-617 RLT augmented by 1 or more cycles of 225 Ac-PSMA-617
Number of subjects: 33
Study 38769923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) management practices
Number of subjects: 3477
Study 38769923 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical characteristics of COPD patients
Number of subjects: 3477
Study 38769974 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine booster dose (third vaccine dose)
Number of subjects: 123
Study 38770009 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 300
Study 38770009 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously every 4 weeks for 52 weeks
Number of subjects: 300
Study 38770592 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib at 6 mg QD
Number of subjects: 203
Study 38770592 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib at 12 mg QD
Number of subjects: 203
Study 38770592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 38770686 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Cannabidiol Administration
Number of subjects: 0
Study 38770686 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard treatment not specified)
Number of subjects: 0
Study 38770764 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38770804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation counselling
Number of subjects: 42273
Study 38770804 — intervention group
Group type: COMPARATOR
Intervention: Counselling interventions of less intensity or shorter duration
Number of subjects: 42273
Study 38770804 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling for at least 15 minutes in the hospital
Number of subjects: 42273
Study 38770804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 42273
Study 38770804 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 42273
Study 38770804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 42273
Study 38770804 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and pharmacotherapy after discharge
Number of subjects: 42273
Study 38770804 — intervention group
Group type: COMPARATOR
Intervention: Post-discharge interventions offering real-time counselling without pharmacotherapy
Number of subjects: 42273
Study 38770804 — intervention group
Group type: COMPARATOR
Intervention: Telephone quitlines
Number of subjects: 42273
Study 38770818 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 65241
Study 38771012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 0
Study 38771012 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute surgery performed in 99/461 patients (21%)
Number of subjects: 461
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger EDH volumes
Number of subjects: 461
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller ASDH volumes
Number of subjects: 461
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline shift
Number of subjects: 461
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-site variation
Number of subjects: 461
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month Glasgow Outcome Scale-Extended scores ≥5
Number of subjects: 461
Study 38771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 461
Study 38771152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of curcuminoids in turmeric extract capsules and acupressure (group 1)
Number of subjects: 72
Study 38771152 — intervention group
Group type: COMPARATOR
Intervention: Placebo and sham acupressure (group 2)
Number of subjects: 72
Study 38771379 — intervention group
Group type: EXPERIMENTAL
Intervention: para-chloro-2-
Number of subjects: 0
Study 38771460 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-point scleral fixation (Akreos AO60)
Number of subjects: 50
Study 38771460 — intervention group
Group type: COMPARATOR
Intervention: Yamane technique (AcrySof MA60AC)
Number of subjects: 50
Study 38771467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily for 4 weeks)
Number of subjects: 11
Study 38771467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 38771476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of Candesartan Cilexetil/Amlodipine/Atorvastatin (16/10/40 mg)
Number of subjects: 0
Study 38771476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of Candesartan Cilexetil/Amlodipine/Atorvastatin (16/5/20 mg)
Number of subjects: 0
Study 38771476 — intervention group
Group type: COMPARATOR
Intervention: Individual formulations of Candesartan Cilexetil, Amlodipine, and Atorvastatin
Number of subjects: 0
Study 38771490 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 92
Study 38771490 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 92
Study 38771490 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15 cmH2O
Number of subjects: 92
Study 38771490 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RRI during PEEP trial
Number of subjects: 92
Study 38771499 — intervention group
Group type: EXPERIMENTAL
Intervention: ropeginterferon-alfa2b (ropegIFNα2b)
Number of subjects: 149
Study 38771622 — intervention group
Group type: EXPERIMENTAL
Intervention: User-Centered Framework for Implementation of Technology (UFIT)
Number of subjects: 41
Study 38771622 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving Pediatric Obesity Practice Using Prompts (integrated package comprising CDS for obesity treatment)
Number of subjects: 41
Study 38771808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Improved Treatment Approaches (AVITA), an interactive, online decision aid
Number of subjects: 30
Study 38771808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Improved Treatment Approaches (AVITA)
Number of subjects: 30
Study 38771906 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stenosis (AS) patients
Number of subjects: 199
Study 38771906 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting AS and transthyretin cardiac amyloidosis
Number of subjects: 199
Study 38771906 — intervention group
Group type: COMPARATOR
Intervention: Controls (no significant coronary artery disease or infarction)
Number of subjects: 199
Study 38771906 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional differences in ECV
Number of subjects: 199
Study 38771911 — intervention group
Group type: EXPERIMENTAL
Intervention: μFR >0.80
Number of subjects: 443
Study 38771911 — intervention group
Group type: COMPARATOR
Intervention: QFR
Number of subjects: 443
Study 38771911 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 443
Study 38771973 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct types of therapy activity preferences
Number of subjects: 621
Study 38771973 — intervention group
Group type: COMPARATOR
Intervention: No specific therapy activity or preference
Number of subjects: 621
Study 38771986 — intervention group
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CARTs
Number of subjects: 11
Study 38771986 — intervention group
Group type: COMPARATOR
Intervention: GD2.CARTs
Number of subjects: 11
Study 38771995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET) (600 mg once daily; 3 weeks on, 1 week off)
Number of subjects: 222
Study 38771995 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (CT) (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine)
Number of subjects: 222
Study 38772477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative stereotactic body radiation therapy (SBRT) delivered using a risk adaptive approach (50 Gy/5 fractions, 60 Gy/8 fractions, 70 Gy/10 fractions)
Number of subjects: 32
Study 38772477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative stereotactic body radiation therapy (SBRT)
Number of subjects: 32
Study 38772517 — intervention group
Group type: EXPERIMENTAL
Intervention: Home modifications and self-management training from an occupational therapist over 4 visits in the home
Number of subjects: 183
Study 38772517 — intervention group
Group type: COMPARATOR
Intervention: Stroke education (control group)
Number of subjects: 183
Study 38772577 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 494
Study 38772577 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone (older age above median 74.6 years)
Number of subjects: 494
Study 38772883 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg Dimethyl fumarate (DMF) orally every day for 6 months
Number of subjects: 60
Study 38772883 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally every day for 6 months
Number of subjects: 60
Study 38772883 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg Dimethyl fumarate (DMF)
Number of subjects: 60
Study 38772883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38772898 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT intervention (Advance Consultations Concerning your Life and Treatment)
Number of subjects: 400
Study 38772898 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study 38772935 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Sustain Nail (MSN)
Number of subjects: 50
Study 38772935 — intervention group
Group type: COMPARATOR
Intervention: Proximal Femoral Nail Antirotation (PFNA)
Number of subjects: 50
Study 38772998 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Number of subjects: 161
Study 38773008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 256
Study 38773008 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 256
Study 38773008 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CADS
Number of subjects: 256
Study 38773189 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20 therapy
Number of subjects: 29
Study 38773199 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine 0.5 g/kg/day by enteral route
Number of subjects: 56
Study 38773199 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study 38773224 — intervention group
Group type: EXPERIMENTAL
Intervention: VT1021
Number of subjects: 22
Study 38773375 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 10, 30, and 60 mg once daily
Number of subjects: 0
Study 38773375 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily
Number of subjects: 0
Study 38773375 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant treatment
Number of subjects: 0
Study 38773375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38773386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie-first approach
Number of subjects: 65
Study 38773386 — intervention group
Group type: COMPARATOR
Intervention: Preloaded bougie approach
Number of subjects: 65
Study 38773386 — intervention group
Group type: COMPARATOR
Intervention: ETT with stylet approach
Number of subjects: 65
Study 38773386 — intervention group
Group type: COMPARATOR
Intervention: ETT without stylet approach
Number of subjects: 65
Study 38773408 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall and fitness-specific METs intensity thresholds derived for older adults.
Number of subjects: 93
Study 38773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient-reported outcomes (PROs) including LURN Symptom Index (SI)-29 and AUA-SI
Number of subjects: 0
Study 38773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine clinical tests integrated with PRO assessment
Number of subjects: 0
Study 38773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric properties of the LURN SIs
Number of subjects: 0
Study 38773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-coordination recommendations based on PROs
Number of subjects: 0
Study 38773457 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (preCRT) with raltitrexed (3 mg/m2 on days 1 and 22) and radiotherapy (50 Gy)
Number of subjects: 68
Study 38773457 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (preCRT)
Number of subjects: 68
Study 38773528 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) 0.4-0.5 mg/kg
Number of subjects: 28
Study 38773543 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-energy diets (VLEDs); specific dosage and duration not mentioned.
Number of subjects: 0
Study 38773543 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study 38773552 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser moxibustion (ILM)
Number of subjects: 140
Study 38773563 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab Q4W
Number of subjects: 450
Study 38773563 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab Q8W
Number of subjects: 450
Study 38773563 — intervention group
Group type: COMPARATOR
Intervention: placebo→guselkumab Q4W (at Week 24)
Number of subjects: 450
Study 38773568 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation programme (Rehab2Life)
Number of subjects: 0
Study 38773568 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38773593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography (HRCT) scan
Number of subjects: 1200
Study 38773595 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4AP)
Number of subjects: 100
Study 38773595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38773608 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in supine position
Number of subjects: 0
Study 38773608 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in upright standing position
Number of subjects: 0
Study 38773608 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in lateral recumbent position
Number of subjects: 0
Study 38773608 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in 45-degree sitting position
Number of subjects: 0
Study 38773608 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP measurements at day 1, 14, 30, and 90 following surgery
Number of subjects: 0
Study 38773643 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) treatment (24 Gy, single fraction)
Number of subjects: 0
Study 38773643 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (continuation of anti-seizure medication and neuromodulation)
Number of subjects: 0
Study 38773653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 2% lidocaine bolus of 1.5 mg/kg with induction of anesthesia, followed by a 2.0 mg/kg/h infusion until the end of surgery
Number of subjects: 1602
Study 38773653 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (normal saline) at the same volume
Number of subjects: 1602
Study 38773653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 2% lidocaine
Number of subjects: 1602
Study 38773653 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (normal saline)
Number of subjects: 1602